ArticleJMIRx med2025
Challenges in Implementing a Mobile AI Chatbot Intervention for Depression Among Youth on Psychiatric Waiting Lists: Randomized Controlled Study Termination Report.
Article in JMIRx med, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Application and effectiveness of artificial intelligence in adolescent mental health support and therapy: a scoping review.BMC psychiatry · 2026Article
- The Impact of Chatbots on Adolescent Mental Health Development: A Comprehensive Literature Review.Journal of multidisciplinary healthcare · 2026Review
- Conversational AI in Pediatric Mental Health: A Narrative Review.Children (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The mental health of children and adolescents is a growing public health concern, with increasing rates of depression and anxiety impacting their emotional, social, and academic well-being. In Japan, access to timely psychiatric care is limited, leading to extended waiting periods that can range from 3 months to a year. Artificial intelligence (AI)-driven chatbots, such as emol (Emol Inc) that integrates acceptance and commitment therapy, show potential as digital solutions to support young patients during these waiting times. The AI chatbot emol was selected based on a comprehensive review of Japanese mental health technology apps, including in-person evaluations with company representatives. Objective: This exploratory parallel-group randomized controlled trial examined the feasibility of using an AI chatbot emol with pediatric and adolescent individuals on psychiatric waiting lists. Methods: Participants aged 12-18 years were recruited from 4 hospitals in Kanagawa Prefecture and randomly assigned to either an intervention group, receiving 8 weekly chatbot sessions, or a control group, receiving standard mental health information. The primary outcome was the change in scores on the 9-item Patient Health Questionnaire from pre- to postintervention. Secondary assessments, such as voice and writing pressure analysis, provided additional engagement metrics, with data collected at baseline, during the intervention, and at week 9. Results: Of the 96 eligible individuals on psychiatric waiting lists, 8 expressed interest and 3 provided initial consent. However, all participants subsequently withdrew or were excluded, resulting in no evaluable data for analysis. Low engagement may have been influenced by the perceived irrelevance of digital tools, complex protocols, and privacy concerns. Conclusions: Significant barriers to engagement suggest that digital interventions may need simpler protocols and trusted environments to improve feasibility. Future studies could test these interventions in supportive settings, like schools or community centers, to enhance accessibility and participation among youth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.